Lauren Biscaldi is the Managing Editor of Drug Topics.
Hormonal Contraceptive Prescribing Benefits Patients, Pharmacies | NCPA 2024
With nearly 7 million women living in a health care desert, pharmacists can provide crucial reproductive care services.
Mid-Meeting Recap | NCPA 2024
The NCPA 2024 Annual Convention and Expo runs through October 29, 2024, in Columbus, Ohio.
Top Tips for Pharmacy Vaccination Clinics | NCPA 2024
Before marketing your pharmacy’s immunizations services, check out these takeaways from NCPA.
Finish The Fight: Patients Can Push PBM Reform Legislation Over the Finish Line | NCPA 2024
PBM reform legislation has progressed further in Congress than ever before.
ACIP Recommendations for Non-Respiratory Immunizations Remain Largely Unchanged | NCPA 2024
A second immunization session focused on updates in meningococcal disease, HPV, and Mpox.
2024 NCPA Digest Highlights Challenges in Independent Pharmacy | NCPA 2024
The digest was released at the NCPA 2024 Annual Convention and Expo.
How to Cash In On Your Pharmacy’s Front End | NCPA 2024
Making the store’s front end a priority can increase revenue opportunities and boost pharmacy profit.
Preparation, Cooperation Keys to Surviving a DEA Inspection | NCPA 2024
The Drug Enforcement Administration gives controlled substance licenses, and can just as easily take them away.
Key Recommendations for 2024-2025 Respiratory Virus Season | NCPA 2024
The first of a 2-part presentation focused on vaccines for COVID-19, flu, RSV, and pneumococcal disease.
ACIP Votes to Lower Recommended Age of Pneumococcal Vaccination
The new recommendations suggest vaccination at age 50, rather than age 65.
FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV
Abrysvo is the only RSV vaccine approved for use in this age group.
Conference Preview: NCPA 2024 Annual Convention and Expo
Oral Semaglutide Reduced MACE Risk in T2D with CVD, CKD
Results of the SOUL clinical trial will be presented at a scientific meeting in 2025.
Rates of Opioid Use Disorder With Gabapentin, Benzodiazepine Coprescription Evaluated
Opioid use disorder risk was higher in a cohort of patients with chronic pain without disability.
Examining Race-Based Disparities in Access to Multimodal Analgesia
Multimodal analgesia provides more effective pain management—and leads to a decrease in opioid use.
Patient-Level Interventions Can Increase HPV Vaccination Rates in Communities | IDWeek 2024
Vaccination against HPV can prevent thousands of cases of cancer each year.
Skeletal Muscle Relaxants May Offer Benefit for Some Types of Chronic Pain
Research is limited on the effectiveness and efficacy of this class of medications.
Managing Medication Overuse Headache in Chronic Migraine
Patients with chronic migraine can frequently overuse acute medications, leading to medication overuse headaches.
At Higher Risk, Vaccine Efficacy, Uptake Are Crucial for Older Adult Populations | IDWeek 2024
Three RSV vaccines are currently FDA approved for use in adults aged 60 or older.
As Meningococcal Disease Rates Rise, Researchers Evaluate Vaccine Efficacy | IDWeek 2024
Cases of meningococcal disease currently exceed prepandemic levels.
New Vaccines in the Pipeline: Norovirus, Lyme Disease, and Combination COVID-19–Flu | IDWeek 2024
Gepotidacin NDA Under Priority Review by FDA for Uncomplicated UTI
Gepotidacin is a first-in-class oral antibiotic with a novel mechanism of action.
Optimizing Heart Failure Outcomes With Medication Management, Screening | ACCP 2024
Pharmacists can screen for social determinants of health and patient beliefs about medications as a way to improve adherence and subsequent outcomes in heart failure.
Research Evaluates Real-World Safety, Efficacy of B/F/TAF Regimen in HIV | ACCP 2024
The first-line B/F/TAF regiment was evaluated in Hispanic/Latino patients, as well as in those with chronic kidney disease.
Medication Adherence Impacts Breast Cancer Outcomes | ESMO 2024
Research from ESMO 2024 focused on the relationship between survival outcomes and medication adherence.
Arexvy Maintains Efficacy Against RSV Over 3 RSV Seasons | CHEST 2024
GSK’s respiratory syncytial virus vaccine continued to provide adults aged 60 years and older with clinically meaningful protection.
American Pharmacists Month Shines a Spotlight on Community Caregiving
GLP-1 Therapies Reduce Risk of Cirrhosis, Complications of MASLD
Investigators compared semaglutide and other glucagon-like peptide-1 receptor agonists with dipeptidyl peptidase-4 inhibitors.
Onyda XR, First Liquid Nonstimulant for ADHD, Now Available in US
The once-daily, extended release, oral suspension medication was approved by the FDA in May 2024.
Higher Vaccination Rates Improve Outcomes in Heart Failure During Respiratory Virus Season
Vaccination against respiratory viruses such as RSV and the flu are crucial to prevent adverse outcomes in patients with heart failure.